Notes
including ritonavir, clarithromycin, itraconazole, voriconazole, or preparations containing cobicistat.
including ergotamine/anhydrous caffeine/isopropylantipyrine (propyphenazone), dihydroergotamine (as mesilate), methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide and quinidine.
Reference
Pharmaceuticals and Medical Devices Agency of Japan. Revisions of PRECAUTIONS (FY2020): Clopidogrel sulfate; Prasugrel hydrochloride; Venetoclax; Posaconazole; Eculizumab (genetical recombination). Internet Document : 8 Dec 2020. Available from: URL: https://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0008.html
Rights and permissions
About this article
Cite this article
PMDA revises precautions and package inserts for five therapeutics. Reactions Weekly 1836, 9 (2021). https://doi.org/10.1007/s40278-021-87828-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-87828-3